Disclosed M&A activity of venture-backed companies rose dramatically in June, thanks to the completion of the $10 billion Stemcentrx acquisition by AbbVie.
Eighteen U.S.-based companies were acquired in June, three of which disclosed their financials, including the outsized Stemcentrx deal. AbbVie announced in late April its intention to buy the South San Francisco developer of cancer therapies from stem cells.
That was a 20 percent uptick in deals from May, when 15 U.S.-based venture-backed companies were acquired. A total of 23 were bought in April.
Altogether, the M&A total of VC-backed companies grew by a factor of 50 in June from May, reaching $10.1 billion in disclosed valuation. The one deal disclosed in May was Boardvantage Inc, which Nasdaq Inc acquired for $200 million.
Downloadable Data: Venture-backed M&A (June 2016)
Photo of a handshake courtesy of ©iStock/johnnyscriv